Multicenter Phase III Study Efficacy of mAb Treatment for Ventilator-Associated Pneumonia (VAP)

About the Case Study

Pharm-Olam was contracted to assess a monoclonal antibody (mAb) treatment for Ventilator-Associated Pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in tandem with standard of care (SOC) antibiotic therapy to determine efficacy, safety, and tolerability of proposed treatment. This made the patient targeting complex and narrow, and Pharm-Olam still delivered. 

Program Overview: Phase 3

Indication: Multicenter Phase 3 Study Efficacy of mAb Treatment for Ventilator-Associated Pneumonia (VAP) with SOC Antibiotics

Sites & Locations: 160 sites, 20+ countries

Pharm-Olam Services:

• Feasibility & Site Solutions
• Project Management
• Clinical Operations & Trial Management
• Data Management
• Medical Affairs & Pharmacovigilance
• Patient Engagement Services
• Biostatistics
• Medical Writing
• Quality Assurance

Download Now